CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.,Cytometry Part B: Clinical Cytometry

当前位置： X-MOL 学术 › Cytom. Part B Clin. Cytom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Cytometry Part B: Clinical Cytometry ( IF 3.4 ) Pub Date : 2020-01-16 , DOI: 10.1002/cyto.b.21866
Pratyusha Gudapati _{1,

2} , Twinkle Khanka _{1,

2} , Gaurav Chatterjee _{1,

2} , Sitaram Ghogale _{1,

2} , Yajamanam Badrinath _{1,

2} , Nilesh Deshpande _{1,

2} , Jagruti Patil _{1,

2} , Gaurav Narula _{2,

3} , Dhanalaxmi Shetty _{2,

4} , Shripad Banavali _{2,

3} , Nikhil V Patkar _{1,

2} , Sumeet Gujral _{2,

5} , Papagudi G Subramanian _{1,

2} , Prashant R Tembhare _{1,

2}

Affiliation

Measurable residual disease (MRD) assessment using multicolor flow cytometry (MFC) has become the center point of pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) risk stratification and therapeutic management. The addition of new markers can improve the accuracy and applicability of MFC‐based MRD assay further. Herein, we evaluated the utility of a new marker, CD304/neuropilin‐1, in the assessment of MFC‐based MRD.

中文翻译：

CD304/neuropilin-1 是一种非常有用且可靠的标志物，可用于评估 B 细胞前体急性淋巴细胞白血病的可测量残留疾病。

使用多色流式细胞术 (MFC) 评估可测量的残留疾病 (MRD) 已成为儿科 B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 风险分层和治疗管理的中心点。新标志物的加入可以进一步提高基于 MFC 的 MRD 检测的准确性和适用性。在此，我们评估了一种新标记物 CD304/neuropilin-1 在评估基于 MFC 的 MRD 中的效用。

更新日期：2020-01-16

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>